Actinium Pharmaceuticals (ATNM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $9.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Justin Walsh has given his Buy rating due to a combination of factors highlighting Actinium Pharmaceuticals’ promising pipeline and strategic partnerships. The company is advancing its ATNM-400 prostate cancer agent, with significant data expected by mid-2025, which could enhance its market potential. Additionally, the initiation of the Phase I/II trial of Iomab-ACT in CAR-T therapy and the expected data release in the second half of 2025 are pivotal developments that could drive future growth.
Moreover, Actinium’s collaboration with the National Cancer Institute under the Cooperative Research and Development Agreement is facilitating the rapid advancement of Actimab-A in acute myeloid leukemia with minimal capital investment. Despite a regulatory setback for Iomab-B in the U.S., the anticipated European approval through its partner Immedica is expected to provide a steady royalty stream, offsetting any negative sentiment. These strategic initiatives and upcoming clinical milestones underpin Walsh’s optimistic outlook on Actinium Pharmaceuticals.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.